November 20, 2019 07:23 AM ESTUpdated 10:45 AM

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund

Natalie Grover

Reporter

Three years after closing out its first €660 million ($730.5 million) private equity fund, London-based GHO Capital Partners has sealed a mammoth $1 billion-plus second …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund